All Stories

Oligomerix small molecule tamps down tau tangles, impro...

An oral small molecule from New York-based biotech Oligomerix curbed the tanglin...

'I don't feel we lost momentum': Takeda’s oncology exec...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are priori...

Pliant, Acelyrin resort to ‘poison pills’ as threat of ...

With Concentra Biosciences expanding its stock influence on Pliant Therapeutics ...

Chutes & Ladders—Gilead's accounting chief hits the exit

Gilead’s Sandra Patterson has “decided to leave the company” after two years in ...

Fierce Biotech Layoff Tracker 2025: Sutro halves staff;...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

Sutro discards CEO, 50% of staff, sole clinical-stage A...

Sutro Biopharma is undergoing a seismic shake-up—jettisoning its CEO, half of it...

J&J's Monarch bronchoscopy robot cleared by FDA to conn...

Dubbed Monarch Quest, the Nvidia-backed AI program can interface with GE HealthC...

Fierce Biotech Layoff Tracker 2025: BMS cuts 57 CA jobs...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

ImmunoPrecise teases $10M ADC, bispecific collab with m...

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leadin...

Eye surgery specialist BVI Medical claims $1B capital r...

BVI said the move fully refinances its debt and adds new equity, both from TPG a...

Hologen AI commits up to $430M to help take MeiraGTx's ...

Artificial intelligence company Hologen AI has committed up to $430 million as p...

Sotio takes up option on ADCs, while Boehringer inks GP...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates, taking...

‘I don't feel we lost momentum’: Takeda’s oncology exec...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are priori...

NIH allegedly cancels dozens of grants for vaccine hesi...

The National Institutes of Health is reportedly continuing its grant-canceling s...

George Church spinout GRObio explores strategic alterna...

Synthetic biology specialist Gro Biosciences, born out of the George Church Lab ...

Samsung backs Alzheimer's blood test developer C2N Diag...

Samsung backed the Alzheimer’s disease blood test developer C2N Diagnostics, wit...

Researchers identify potential MASH target after gene d...

Researchers at Waseda University in Japan have identified a gene that, when rend...

Clario acquires WCG's neuroscience-focused clinical out...

Tech firm Clario is boosting its electronic clinical outcome assessment (eCOA) o...

J&J’s Monarch bronchoscopy robot cleared by FDA to conn...

Dubbed Monarch Quest, the Nvidia-backed AI program can interface with GE HealthC...

GSK posts data on HIV assets vying for roles in 6-month...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HI...

Insilico Medicine raises $110M for new trials and robot...

Insilico's series E round was led by Hong Kong-based firm Value Partners, and jo...

Manufacturer fuels Swiss biotech’s next-gen vaccine por...

Emergent BioSolutions is investing in Swiss biotech Rocketvax, inking a deal des...

Harbour BioMed launches new obesity biotech on mission ...

China’s Harbour BioMed has launched a new biotech to develop bispecific antibodi...

Roche pads out obesity pipeline, paying Zealand $1.6B u...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.